Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer.
Nardi F, Perurena N, Schade AE, Li ZH, Ngo K, Ivanova EV, Saldanha A, Li C, Gokhale PC, Hata AN, Barbie DA, Paweletz CP, Jänne PA, Cichowski K.
Nardi F, et al. Among authors: janne pa.
J Clin Invest. 2023 Aug 15;133(16):e167651. doi: 10.1172/JCI167651.
J Clin Invest. 2023.
PMID: 37384411
Free PMC article.